CliffBio
biologic

Survanta

beractant

Loss of exclusivityJuly 2003projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameSurvanta
Active ingredientberactant
Strength200MG/8ML (25MG/ML)
Dosage formSuspension
RouteIntratracheal
ModalityBiologic
FDA approvalJuly 1991
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Survanta patent cliff — loss of exclusivity July 2003 | CliffBio